People in the News

Jul 13, 2018

David Byram

GeneNews announced that it has appointed David Byram as Chief Commercial Officer for its US lab, Innovative Diagnostics Laboratory (IDL). Byram will oversee all of the IDL customer's-facing activities, including sales, client relations, and commercial operations. Prior to joining IDL, Byram was VP, commercial and government affairs for Braeburn Pharmaceuticals. Prior to Braeburn, Byram held positions as senior VP, commercial affairs for Orexo AB/US, US director, public sector for Indivior, and senior director, strategic accounts and public affairs for Janssen Biotech. 

Jul 12, 2018

Johnson Chiang, Rixun Fang

Johnson Chiang has been appointed chief technology officer and Rixun Fang director of assay development at Alveo Technologies.

Chiang was previously head of systems integration and molecular biology at Foundation Medicine. He also held senior management positions at Life Technologies and at Thermo Fisher Scientific. Prior to that, he led molecular diagnostic product development projects at Applied MEMS, Applied Biosystems, and Cepheid.

Fang previously led several molecular biology research and IVD development projects at Applied Biosystems, Life Technologies, and Thermo Fisher Scientific.

Jul 12, 2018

Freenome Impact Advisory Board

Freenome has announced the creation of what it calls its Impact Advisory Board, a group tasked with helping the company optimize strategies, including those that will guide its first commercial launch of a blood-based, artificial intelligence-derived genomic test for the early detection of colorectal cancer.

The new board includes NDA Partners' Alberto Gutierrez, a former 25-year veteran of the US Food and Drug Administration, who will be tasked with guiding regulatory strategy. Joining Gutierrez are two experts on payor strategy: Louis Jacques, chief clinical officer of ADVI Health and former head of the Centers for Medicare and Medicaid Services' Coverage and Analysis Group; and Sherie Smalley, senior medical director of medical policy at UPMC Health Plan.

It also includes clinical development advisors with expertise in gastroenterology, including Douglas Robertson from the US Multi-Society Task Force of Colorectal Cancer.

Jul 10, 2018

Michael Sussman, Christopher Bradfield

Michael Sussman will become director of the Genome Center of Wisconsin, which is located within the University of Wisconsin-Madison Biotechnology. To assume his new role, he is stepping down as director of the Biotechnology Center. Christopher Bradfield, a professor of oncology at UW-Madison, has been named interim director of the Biotechnology Center.

Jul 10, 2018

Christopher Benoit

Christopher Benoit has been appointed as CEO of TwinStrand Biosciences after joining the company's board of directors earlier this year. Previously, he held various roles at Enzymatics, a company he co-founded. Qiagen acquired Enzymatis in 2014. He is also a member of the board of TangenDX, a point-of-care molecular diagnostics company.

Jul 10, 2018

Fayyaz Memon

Immunexpress has appointed Fayyaz Memon as the firm's VP of regulatory affairs and quality. With over 25 years of experience in the life science industry, Memon has previously served in leadership positions at Asuragen, Qiagen, PrimeraDx, Thermo Fisher Scientific, Digene, SmithKline Beecham, and Johnson & Johnson.

Jul 10, 2018

Violaine Mélen, Stéphane Cruveiller

PathoQuest has appointed Violaine Mélen as its head of quality assurance and regulatory affairs. In the new position, Mélen will oversee the maintenance of product quality and compliance in line with the firm's quality management system, while also leading the firm's regulatory strategies. She has more than 12 years of experience in regulatory affairs, quality assurance, and clinical affairs within the biotech and pharmaceutical industries. Mélen previously worked at Bio-Rad Laboratories where she was responsible for implementing risk management procedures with a specific focus on infectious disease.

In addition, PathoQuest has appointed Stéphane Cruveiller as its chief technology information officer. As CTIO, Cruveiller will be responsible for the technical aspects of the firm's bioinformatics pipeline and alignment information technology-related development initiatives with its business goals. Cruveiller previously served as team leader at the François Jacob Institute of Biology - Genoscope of the French Alternative Energies and Atomic Energy Commission at the Laboratory of Bioinformatics Analyses for Genomics and Metabolism.

Jul 09, 2018

George Golumbeski, Onaiza Cadoret-Manier, Fred Kohler, Angela Lai

Grail has added to its executive team, hiring George Golumbeski as president, Onaiza Cadoret-Manier as chief commercial officer, and Fred Kohler as vice president of people. The firm has also promoted Angela Lai to chief technology officer.

Golumbeski most recently served as executive vice president of business development for Celgene, and currently serves on the boards of several biotechnology companies, including KSQ Therapeutics, Carrick Therapeutics, Enanta Pharmaceuticals, and MorphoSys. He will replace Ken Drazan as president, who has stepped down to work on helping early-stage start-up firms secure funding. Drazan will continue to serve as an advisor to Grail. Golumbeski will also join Grail's board of directors.

Cadoret-Manier joins Grail from Genentech where she was vice president of the respiratory franchise. Previously, she held various senior management positions overseeing sales and marketing for several products at Genentech, Pfizer, Amylin Pharmaceuticals, and Quest Diagnostics.

Kohler has joined Grail from Roche, where he most recently led transformation work. Kohler previously worked at Autodesk and Juniper Networks, where he held a variety of human resources roles.

Lai has served as vice president of clinical technology at Grail since July 2016. She was responsible for building Grail's software systems team and supporting the company's clinical studies.

Jul 06, 2018

Lyn Rees, Stephen Little, Keng Hsu

Lyn Rees has become CEO of Premaitha Health, replacing Stephen Little, who is now the company's executive vice chairman. Rees joins Premaitha from BBI Group, where he was most recently CEO.

In addition, Keng Hsu has become Premaitha's chief operating officer for Asia. He used to be CFO of Yourgene Bioscience, which Premaitha acquired last year.

Furthermore, Alan Chang has stepped down as non-executive director of Premaitha to focus on other business interests.

Jul 03, 2018

Armin Winands and Jan Hellemans

Belgian genomics service provider Biogazelle has appointed Armin Winands as its new CEO. Winands most recently served as director of business development at ArcherDX. Over the past 23 years, he has also held senior sales positions at NuGEN Technologies, Ingenuity Systems, Ion Torrent Systems, Illumina, Affymetrix, and Molecular Dynamics. Winands replaces Jan Hellemans, who served as CEO of Biogazelle for the past 10 years and will now take on the role of chief technology officer.

Jul 03, 2018

Paul Kinnon

Paul Kinnon has been appointed CEO of PredictImmune in Cambridge, UK. He previously held leadership positions at Transgenomic, ZyGem, Life Technologies, Guava Technologies, and Cellomics. Kinnon started his career as an analytical chemist at Smithkline French & Beckman Research, a predecessor of GlaxoSmithKline.

Jul 03, 2018

Todd Nelson

SGI-DNA has appointed Todd Nelson as CEO to lead its spin out from Synthetic Genomics. Nelson has led several life sciences companies through phases of financial and commercial growth, including eBioscience (which was acquired by Affymetrix), MP Biomedicals (which was acquired by Valeant Fine Chemicals), and DiscoverX Corporation (now Eurofins), SGI-DNA said. He is also the founder of Tonbo Biosciences and TCRx Corporation.

Jun 28, 2018

Amy Abernethy

CareDx has appointed Amy Abernethy to its board of directors. Abernethy is chief medical officer, CSO, and senior vice president for oncology for Flatiron Health. She also serves on the board for Athenahealth. Before joining Flatiron, Abernethy was a professor of medicine at Duke University School of Medicine and ran the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute. She maintains an adjunct professorship with Duke.

Jun 28, 2018

Ajay Gopal, Deena Bahri

Helix has hired Ajay Gopal as chief financial officer and Deena Bahri as chief marketing officer. Gopal was most recently vice president and CFO at StubHub and before that held several roles at eBay and GE Healthcare. Bahri was previously chief marketing officer at startup juice company Juicero and before that chief marketing officer at Birchbox.

Jun 27, 2018

David King

Fluidigm has appointed David King VP of R&D, genomics. He joins the firm from IntegenX, where he was executive VP, product development. King also previously held the position of VP of product development at Affymetrix, and VP of R&D and operations at Guava Technologies.

Jun 26, 2018

Brian Brille, Michael Sullivan, Nicholas Nelson

Caris Life Sciences appointed Brian Brille as vice chairman, Michael Sullivan as chief commercial officer, and Nicholas Nelson as chief business officer. Brille will be responsible for corporate and business development, M&A, and capital markets. He has more than 25 years of experience as a senior financial services executive. Most recently, he was president of Asia Pacific for Bank of America Merrill Lynch. Before that, he was global head of corporate and investment banking at Bank of America. 

Before joining Caris, Sullivan was at Roche Diagnostics where he was most recently senior vice president, general manager, and business unit lifecycle leader of the company's core oncology franchise. He also held commercial leadership roles at Johnson & Johnson Ortho-Clinical Diagnostics and Abbott Laboratories' diagnostics division. 

Nelson was vice president of commercial and corporate development at Trovagene before joining Caris. He also spent 10 years at Illumina in R&D, technical service, and sales. 

Jun 25, 2018

Reinhard Ambros

Reinhard Ambros has joined the board of directors of Synthetic Genomics. He was the global head of the Novartis Venture Fund from 2005 until 2017. Prior to that, he was head of group strategic planning at Novartis and led business development and licensing in the cardiovascular and metabolic disease area for Novartis Pharma. Ambros holds a PhD from the University of Regensburg in Germany.

Jun 21, 2018

Garrett Lam

Garrett Lam will join Sera Prognostics as chief medical officer starting Sept. 4. He will direct all clinical development activities for the firm and direct a group of clinical operations professionals in support of the firm's collaborations. Lam is currently a professor and chairman of obstetrics and gynecology at the University of Tennessee College of Medicine-Chattanooga. Lam replaces Durlin Hickok, who has been Sera's CMO since 2011. Hickok will continue as an advisor to Sera. 

Jun 20, 2018

Kenneth Bloom

Kenneth Bloom has become chief medical officer of advanced pathology and genomic services at Invicro and Ambry Genetics, both part of Konica Minolta. Previously, he was president and head of oncology and immunotherapy at Human Longevity, and before that, chief medical officer of in vitro diagnostics, life sciences at General Electric. He also served as president and CEO of the medical group of Clarient Pathology Services, which was acquired by GE. Prior to that, he held various academic positions, including director of laboratory operations and chief information officer at the Rush Cancer Institute, clinical professor of pathology at the University of Southern California Keck School of Medicine, and associate professor of pathology at Rush Medical College. Bloom holds an MD from Rush Medical College and a BA from Grinnell College.

Jun 18, 2018

Joseph Caruso

LexaGene has appointed Joseph Caruso to the its board of directors. Caruso currently serves as a member of the board of directors and operating committee at Endocellutions. Caruso was previously CEO and chairman of Palomar Medical Technology until the firm's sale in 2013. 

Jun 15, 2018

Lihau Yu

Eisai announced today that it has appointed Lihau as president and chief data sciences officer of H3 Biomedicine, the cancer genomics-based drug discovery company of Eisai. Yu will be responsible for the overall scientific and business direction of H3, where she joined H3 in 2011. Yu previously spent 12 years at AstraZeneca. 

Jun 13, 2018

Lawrence Firestone

Akonni Biosystems has appointed Lawrence Firestone to the role of executive vice president and CFO to bring the company through the commercialization phase of its business plan. Firestone has previously served as CEO, CFO, and COO in various technology firms.

Jun 13, 2018

Rohan Hastie, John Ryals,

Rohan Hastie was named president and CEO of Metabolon. He replaces John Ryals, who retired from those posts, but will remain on the company's board. Ryals has been president, CEO, and a board member of Metabolon since April 2002, when he cofounded the firm. 

Hastie joined Metabolon in September 2017 as chief business officer. Before that, he was president of consulting firm Arrow Life Sciences & Healthcare. He also has held leadership positions in diagnostics and corporate development at Hologic, where he was most recently president of Hologic Diagnostic Solutions.

Jun 12, 2018

Michael McCartney

Cancer Genetics has appointed Michael McCartney its chief commercial officer, effective immediately. McCartney was previously CEO of SciKon Innovation, an early-stage life science company. Before that, he was SciKon's COO. He has more than 20 years of experience in the life science space including stints at Roche, Siemens, and Abbott. 

Jun 08, 2018

Gerald Herman

Bruker announced that it has hired Gerald Herman as its new CFO. He replaces Anthony Mattacchione, whose resignation was announced in February. Herman joined Bruker in 2016 as VP and corporate controller, and has been serving as interim CFO since March 2018. He previously served a corporate VP - Clinical Operations of Parexel International from 2014 to February 2016, and as corporate VP and controller-finance of Parexel from 2008 to 2013. Prior to 2008, he was VP - corporate controller of Presstek.

Pages

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.